WebInitiate statin therapy. (Non-statin medications should be considered only in statin-intolerant patients.) • Discuss with patient: risk reduction benefits, adverse effects, drug interactions, patient preferences. Check baseline ALT. (See Table 4for monitoring if … WebSystemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. Its course is typically recurrent, with periods of relative remission followed by …
AAFP Affirms Value of New Cholesterol Management …
WebAge 40 to 75, 10-year ASCVD risk ≥ 7.5% (if unable to tolerate high-intensity statin) Age 40 to 75, 10-year ASCVD risk 5 to < 7.5%. Atorvastatin 10-20 mg. Fluvastatin XL 80 mg. Lovastatin 40 mg. Pitavastatin 2-4 mg. Pravastatin 40-80 mg. Rosuvastatin 5 … WebWalk through the steps of treating and managing a patient who reports muscle symptoms, including cycles of statin discontinuation and rechallenge to identify a tolerated statin and … redacted update
Key Recommendations on Managing Dyslipidemia for Cardiovascular ... - AAFP
WebReducing LDL cholesterol levels with statins provides only a small absolute reduction in the person's overall likelihood of dying (0.8% reduction), having a myocardial infarction (1.3%), or having ... WebStatin benefi t groups The new guidelines keep the same statin benefi t groups defi ned in the previous (2013) ACC/AHA guidelines.8 Statin therapy recommendations are specifi cally given for the following groups: Adults with severe hypercholesterolemia If a patient age 20 to 75 has LDL-C levels of 190 mg/dL or higher, you do not need to cal- WebFeb 26, 2024 · February 26, 2024. On Feb. 18, the U.S. Preventive Services Task Force (USPSTF) published a revised version of its 2016 final recommendation statement on Statin Use for the Primary Prevention of Cardiovascular Disease (CVD) in Adults. In the Feb. 18 email to USPSTF Dissemination and Implementation Partners, USPSTF said, “after … redacted voice